In an effort to fulfill his campaign promise of lowering drug prices, President Trump has recently struck a deal with pharmaceutical company AstraZeneca to reduce prices for certain medications under the Medicaid program.
The agreement, announced by the White House on Monday, aims to make prescription drugs more affordable for millions of Americans who rely on government-funded health insurance. AstraZeneca has agreed to lower the prices of several of its most popular drugs, including those used to treat conditions such as diabetes, asthma, and high blood pressure.
Under the terms of the deal, AstraZeneca will also provide rebates to the federal government for certain medications, further reducing the cost burden on taxpayers. The move comes as part of Trump's broader efforts to tackle rising healthcare costs and make prescription drugs more affordable for all Americans.
Critics of the deal have raised concerns about the impact on AstraZeneca's bottom line, but supporters argue that the move is a step in the right direction towards addressing the issue of skyrocketing drug prices in the United States. As the debate over healthcare reform continues, the deal between Trump and AstraZeneca marks a significant milestone in the push to lower prescription drug costs for American patients.
Category: Politics
Published on: 2025-10-12 12:47:38
Related articles:
Trump Cuts a Deal With AstraZeneca to Lower Drug Prices, New York Times
AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs, The Guardian
Trump unveils deal for AstraZeneca to cut Medicaid drug prices and join "TrumpRx" site, CBS News
Tags: astrazeneca drug prices
AstraZeneca, one of the leading pharmaceutical companies, has announced the cancellation of its £450m investment in the Speke expansion project. The decision came as a result of a cut in state funding, leaving the company with no choice but to reallocate their resources.
The project, which aimed to boost manufacturing capabilities in the UK, was a significant part of AstraZeneca's growth strategy. However, the company's CEO, Chris Brant, stated that without the necessary financial support from the government, the project was no longer viable.
The cancellation of the Speke project has raised concerns about the future of AstraZeneca's presence in the UK. Nils Pratley, a finance expert, criticized the UK government for failing to support such a crucial investment, highlighting the potential negative impact on both the company and the UK economy.
AstraZeneca's decision to withdraw the £450m investment highlights the challenges faced by businesses in an uncertain economic climate. The company's focus will now shift to other projects that can deliver a higher return on investment in the absence of government backing for the Speke expansion.
Category: Finance
Published on: 2025-02-03 18:30:29
Related articles:
AstraZeneca’s U-turn on £450m Speke expansion ‘deeply disappointing’, says minister, The Guardian
AstraZeneca’s £450m Speke exit looks terrible for a pro-growth government | Nils Pratley, The Guardian
AstraZeneca cancels £450m Speke project, blaming cut in state funding, The Guardian
Tags: astrazeneca £450m speke